Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $9.1 million.

  • Veracyte's Change in Accured Expenses rose 4552500.0% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 101.27%. This contributed to the annual value of $3.5 million for FY2024, which is 62381.66% up from last year.
  • As of Q3 2025, Veracyte's Change in Accured Expenses stood at $9.1 million, which was up 4552500.0% from $6.8 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Change in Accured Expenses peaked at $12.9 million during Q2 2024, and registered a low of -$9.0 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $1.1 million, with a median of $238000.0 in 2021.
  • Per our database at Business Quant, Veracyte's Change in Accured Expenses crashed by 187974.36% in 2023 and then skyrocketed by 4552500.0% in 2025.
  • Veracyte's Change in Accured Expenses (Quarter) stood at $11.1 million in 2021, then crashed by 81.02% to $2.1 million in 2022, then rose by 29.34% to $2.7 million in 2023, then crashed by 112.89% to -$351000.0 in 2024, then skyrocketed by 2699.72% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $6.8 million for Q2 2025, and -$8.9 million during Q1 2025.